Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques

An HIV vaccine would thwart the spread of HIV infection and save millions of lives. Unfortunately, the immune responses conferring universal protection from HIV infection are poorly defined. The innate immune system, including the complement system, is an evolutionarily conserved, basic means of protection from infection. Complement can prevent infection by directly lysing incoming pathogens. We found that vaccination against SIV in rhesus macaques induces antibodies that are capable of directing complement lysis of SIV and SIV-infected cells in both sexes. We also found sex differences in vaccine-induced antibody species and their functions. Overall, our data suggest that sex affects vaccine-induced antibody characteristics and function and that males and females might require different immune responses to protect against HIV infection. This information could be used to generate highly effective HIV vaccines for both sexes in the future. ABSTRACT An effective human immunodeficiency virus (HIV) vaccine has yet to be developed, and defining immune correlates of protection against HIV infection is of paramount importance to inform future vaccine design. The complement system is a component of innate immunity that can directly lyse pathogens and shape adaptive immunity. To determine if complement lysis of simian immunodeficiency virus (SIV) and/or SIV-infected cells represents a protective immune correlate against SIV infection, sera from previously vaccinated and challenged rhesus macaques were analyzed for the induction of antibody-dependent complement-mediated lysis (ADCML). Importantly, the vaccine regimen, consisting of a replication-competent adenovirus type 5 host-range mutant SIV recombinant prime followed by a monomeric gp120 or oligomeric gp140 boost, resulted in overall delayed SIV acquisition only in females. Here, sera from all vaccinated animals induced ADCML of SIV and SIV-infected cells efficiently, regardless of sex. A modest correlation of SIV lysis with a reduced infection rate in males but not females, together with a reduced peak viremia in all animals boosted with gp140, suggested a potential for influencing protective efficacy. Gag-specific IgG and gp120-specific IgG and IgM correlated with SIV lysis in females, while Env-specific IgM correlated with SIV-infected cell lysis in males, indicating sex differences in vaccine-induced antibody characteristics and function. In fact, gp120/gp140-specific antibody functional correlates between antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis, and ADCML as well as the gp120-specific IgG glycan profiles and the corresponding ADCML correlations varied depending on the sex of the vaccinees. Overall, these data suggest that sex influences vaccine-induced antibody function, which should be considered in the design of globally effective HIV vaccines in the future. IMPORTANCE An HIV vaccine would thwart the spread of HIV infection and save millions of lives. Unfortunately, the immune responses conferring universal protection from HIV infection are poorly defined. The innate immune system, including the complement system, is an evolutionarily conserved, basic means of protection from infection. Complement can prevent infection by directly lysing incoming pathogens. We found that vaccination against SIV in rhesus macaques induces antibodies that are capable of directing complement lysis of SIV and SIV-infected cells in both sexes. We also found sex differences in vaccine-induced antibody species and their functions. Overall, our data suggest that sex affects vaccine-induced antibody characteristics and function and that males and females might require different immune responses to protect against HIV infection. This information could be used to generate highly effective HIV vaccines for both sexes in the future.

[1]  Allan C. deCamp,et al.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144 , 2017, PloS one.

[2]  Karen G. Dowell,et al.  Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles , 2017, Journal of immunological methods.

[3]  H. Campbell,et al.  Estrogens regulate glycosylation of IgG in women and men. , 2017, JCI insight.

[4]  D. Venzon,et al.  B Cell Responses Associated with Vaccine-Induced Delayed SIVmac251 Acquisition in Female Rhesus Macaques , 2016, The Journal of Immunology.

[5]  D. Lauffenburger,et al.  A Functional Role for Antibodies in Tuberculosis , 2016, Cell.

[6]  I. R. de Souza,et al.  BAFF Expression is Modulated by Female Hormones in Human Immune Cells , 2016, Biochemical Genetics.

[7]  Qingsheng Li,et al.  Vaccine Induction of Lymph Node–Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques , 2016, The Journal of Immunology.

[8]  S. Gianella,et al.  Barriers to a cure for HIV in women , 2016, Journal of the International AIDS Society.

[9]  S. Thiel,et al.  Complement activation, regulation, and molecular basis for complement‐related diseases , 2015, The EMBO journal.

[10]  Jerome H. Kim,et al.  Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology , 2015, Cell.

[11]  J. Lünemann,et al.  Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. , 2015, The Journal of clinical investigation.

[12]  B. Haynes,et al.  Immune correlates of vaccine protection against HIV-1 acquisition , 2015, Science Translational Medicine.

[13]  D. Montefiori,et al.  Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge , 2015, PLoS pathogens.

[14]  H. Schuitemaker,et al.  Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.

[15]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[16]  H. Hackl,et al.  Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells , 2015, PLoS pathogens.

[17]  Lubka T. Roumenina,et al.  Complement System Part II: Role in Immunity , 2015, Front. Immunol..

[18]  J. Lifson,et al.  Complement Opsonization of HIV-1 Results in Decreased Antiviral and Inflammatory Responses in Immature Dendritic Cells via CR3 , 2014, The Journal of Immunology.

[19]  J. Schiller,et al.  Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development , 2014, PLoS pathogens.

[20]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[21]  M. Hassall,et al.  Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS , 2014, PloS one.

[22]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[23]  Kai-Ting C. Shade,et al.  Antibody Glycosylation and Inflammation , 2013 .

[24]  T. Kuijpers,et al.  Mannose-binding Lectin and the Risk of HIV Transmission and Disease Progression in Children: A Systematic Review , 2012, The Pediatric infectious disease journal.

[25]  J. Köhl,et al.  The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. , 2012, Immunobiology.

[26]  Udo Albus,et al.  Book Review: Guide for the Care and use of Laboratory Animals , 1998 .

[27]  L. Qiu,et al.  Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. , 2012, Journal of proteomics.

[28]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[29]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[30]  Pauline M. Rudd,et al.  High Throughput Isolation and Glycosylation Analysis of IgG–Variability and Heritability of the IgG Glycome in Three Isolated Human Populations* , 2011, Molecular & Cellular Proteomics.

[31]  I. Williams,et al.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection , 2011, Retrovirology.

[32]  K. Skjoedt,et al.  Sodium Polyanethole Sulfonate as an Inhibitor of Activation of Complement Function in Blood Culture Systems , 2009, Journal of Clinical Microbiology.

[33]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[34]  D. Fremont,et al.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. , 2009, Cell host & microbe.

[35]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[36]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[37]  E. Terpos,et al.  Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[38]  A. Trkola,et al.  Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.

[39]  J. Lifson,et al.  Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.

[40]  J. Sodroski,et al.  Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[41]  D. Cornforth,et al.  Detection of Antibody-Dependent Complement-Mediated Inactivation of both Autologous and Heterologous Virus in Primary Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.

[42]  O. Spiller,et al.  The relevance of complement to virus biology , 2004, Virology.

[43]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[44]  F. Steindl,et al.  Detachment of Human Immunodeficiency Virus Type 1 from Germinal Centers by Blocking Complement Receptor Type 2 , 2000, Journal of Virology.

[45]  D. Zurakowski,et al.  A statistically defined endpoint titer determination method for immunoassays. , 1998, Journal of immunological methods.

[46]  J. Atkinson,et al.  Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. , 1997, The Journal of general virology.

[47]  N. Takahashi,et al.  Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum , 1997, Glycoconjugate Journal.

[48]  H. Okada,et al.  Presence of IgM Antibodies Which Sensitize HIV‐1‐Infected Cells to Cytolysis by Homologous Complement in Long‐Term Survivors of HIV Infection , 1997, Microbiology and immunology.

[49]  B. Sha,et al.  Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. , 1996, Journal of immunology.

[50]  M. Dierich,et al.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) , 1996, The Journal of experimental medicine.

[51]  D. Montefiori New insights into the role of host cell proteins in antiviral vaccine protection. , 1995, AIDS research and human retroviruses.

[52]  J. Schmitz,et al.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. , 1995, The Journal of clinical investigation.

[53]  S. Zolla-Pazner,et al.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1 , 1995, The Journal of experimental medicine.

[54]  D. Montefiori,et al.  Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. , 1994, Virology.

[55]  G. Opelz,et al.  Complement activation by recombinant HIV-1 glycoprotein gp120. , 1994, Journal of immunology.

[56]  S. Thiel,et al.  Complement activation upon binding of mannan‐binding protein to HIV envelope glycoproteins , 1993, AIDS.

[57]  S. Zolla-Pazner,et al.  Complement activation by human monoclonal antibodies to human immunodeficiency virus , 1993, Journal of virology.

[58]  M. Kazatchkine,et al.  Decreased Expression of the Membrane Inhibitor of Complement‐Mediated Cytolysis CD59 on T‐lymphocytes of HIV‐Infected Patients , 1992, AIDS.

[59]  N. Thielens,et al.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41 , 1991, The Journal of experimental medicine.

[60]  L. Gritz,et al.  Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.

[61]  D. Vergani,et al.  Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. , 1990, The Journal of infectious diseases.

[62]  J. Hilfenhaus,et al.  Antibody‐ and complement‐mediated lysis of HIV‐infected cells and inhibition of viral replication , 1990, Journal of medical virology.

[63]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[64]  M. Frank,et al.  Therapeutic potential of complement modulation , 2010, Nature Reviews Drug Discovery.

[65]  M. Carroll,et al.  The role of complement and complement receptors in induction and regulation of immunity. , 1998, Annual review of immunology.

[66]  C. Parker,et al.  Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. , 1994, AIDS research and human retroviruses.

[67]  Global AIDS update. , 1992, World health forum.

[68]  Critchlow E. Douglas,et al.  On distribution-free multiple comparisons in the one-way analysis of variance , 1991 .